21 results
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
11 Mar 24
Other Events
4:09pm
Demographics Parameter Statistic All placebo (n=7) 25 mg CTI-1601 (n=6) 50 mg CTI-1601 (n=7) 100 mg CTI-1601 (n=7) All CTI-1601 (n=20) Overall (n=27) Sex Male n … evaluating once-daily and every-other-day dosing regimens for CTI-1601
Phase 2 Demographic/ Disease Characteristics Data
Demographics – Phase 2
8-K
EX-99.3
LRMR
Larimar Therapeutics Inc
12 Feb 24
Results of Operations and Financial Condition
7:03am
)
Demographics – Phase 2 Trial 25 mg Cohort 50 mg Cohort Placebo N = 4 Nomlabofusp N = 9 Overall N = 13 Placebo N = 5 Nomlabofusp N = 10 Overall N = 15 Age
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
12 Feb 24
Results of Operations and Financial Condition
7:03am
on nomlabofusp; 5 on placebo)
Demographics – Phase 2 Trial 25 mg Cohort 50 mg Cohort Placebo N = 4 Nomlabofusp N = 9 Overall N = 13 Placebo N = 5 …
MAD Trial Patient Demographics Parameter Statistic All placebo (n=7) 25 mg CTI-1601 (n=6) 50 mg CTI-1601 (n=7) 100 mg CTI-1601 (n=7) All CTI-1601 (n
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
Cells) FXN* Change from Baseline By Dose Group (Buccal Cells)
MAD Trial Patient Demographics Parameter Statistic All placebo (n=7) 25 mg CTI-1601 (n=6 … * Change from Baseline (Buccal Cells)#
Demographics of Phase 2 (Cohort 1) Demographics similar between Phase 1 and Phase 2 trials of CTI-1601 Parameter
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Aug 23
Other Events
8:00am
By Dose Group (Skin Cells) FXN* Change from Baseline By Dose Group (Buccal Cells)
MAD Trial Patient Demographics Parameter Statistic All placebo (n=7) 25 … at Day 14. FXN* Change from Baseline (Buccal Cells) Day 14 FXN* Change from Baseline (Buccal Cells)#
Demographics of Phase 2 (Cohort 1) Demographics
8-K
EX-99.1
mpfdn06
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.2
2lteyzw
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.2
a6jlnpu
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
eujx2ite
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-99.2
2qw8pjmqdpnav3hua
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
hct7vuu q4b
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
mxy4x
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.2
ylkxtawxm
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
EX-99.1
6zfe32 51d5o6r
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
EX-99.2
mox1mn zzs
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
EX-99.2
r2jp55y
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-99.1
t6ckyxonwj sm9
1 Jul 21
Other Events
6:11am
8-K
EX-99.1
wjhax
14 Jun 21
Other Events
5:21pm
8-K
EX-99.1
6ikq31xl
18 May 21
Other Events
3:09pm
8-K
EX-99.1
8cmwxp0
11 May 21
Other Events
8:34am